Reports Q2 revenue $264.6M, consensus $262M. “Acadia continued to build momentum in the second quarter, resulting in total revenue of $264.6 million,” said Catherine Owen Adams, Chief Executive Officer. “NUPLAZID delivered a very strong quarter, particularly in terms of referrals and new patient starts, driven by strong commercial execution and increased engagement from our direct-to-consumer campaigns. DAYBUE grew 14% year-over-year and reached its highest paid patient count to date, reflecting disciplined execution of our plan to accelerate growth. In addition, we recently hosted our inaugural R&D Day showcasing the depth of our pipeline and its potential to drive our long-term value.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACAD Earnings this Week: How Will it Perform?
- Cautious Outlook on ACADIA Pharmaceuticals Amid Market Penetration and Growth Uncertainties
- Taysha Gene Therapies initiated with a Buy at BofA
- Acadia Pharmaceuticals price target raised to $22 from $19 at Oppenheimer
- ACADIA Pharmaceuticals: Promising Pipeline and Strategic Investments Drive Buy Rating